Abciximab

DB00054

biotech approved

Deskripsi

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (?v?3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production. Excreted renally.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive antiplatelet activity may increase the risk of bleeding. Examples include ginseng, ginkgo, ginger, and garlic.

Interaksi Obat

978 Data
Apixaban Apixaban may increase the anticoagulant activities of Abciximab.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Abciximab.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Abciximab.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Abciximab is combined with Deferasirox.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Abciximab.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Abciximab.
Rivaroxaban Abciximab may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Abciximab is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Abciximab.
Urokinase Urokinase may increase the anticoagulant activities of Abciximab.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Abciximab.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Abciximab is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Abciximab is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Abciximab is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Abciximab is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Abciximab is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Abciximab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.
Obinutuzumab The risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.
Tipranavir Tipranavir may increase the antiplatelet activities of Abciximab.
Vitamin E Vitamin E may increase the antiplatelet activities of Abciximab.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Abciximab.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Abciximab.
Quinine The therapeutic efficacy of Abciximab can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Abciximab can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Abciximab.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Abciximab.
Pentoxifylline The therapeutic efficacy of Abciximab can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Abciximab.
Levocarnitine The therapeutic efficacy of Abciximab can be increased when used in combination with Levocarnitine.
Dienestrol Dienestrol may increase the thrombogenic activities of Abciximab.
Promestriene Promestriene may increase the thrombogenic activities of Abciximab.
Estrone Estrone may increase the thrombogenic activities of Abciximab.
Dextran Dextran may increase the anticoagulant activities of Abciximab.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Abciximab.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Abciximab.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Abciximab.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Abciximab.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Abciximab.
Quinestrol Quinestrol may decrease the anticoagulant activities of Abciximab.
Hexestrol Hexestrol may decrease the anticoagulant activities of Abciximab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Abciximab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Abciximab.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Abciximab.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Abciximab.
Zeranol Zeranol may decrease the anticoagulant activities of Abciximab.
Equol Equol may decrease the anticoagulant activities of Abciximab.
Methallenestril Methallenestril may decrease the anticoagulant activities of Abciximab.
Epimestrol Epimestrol may decrease the anticoagulant activities of Abciximab.
Moxestrol Moxestrol may decrease the anticoagulant activities of Abciximab.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Abciximab.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Abciximab.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Abciximab.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Abciximab.
Biochanin A Biochanin A may decrease the anticoagulant activities of Abciximab.
Formononetin Formononetin may decrease the anticoagulant activities of Abciximab.
Estriol Estriol may decrease the anticoagulant activities of Abciximab.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Abciximab.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Abciximab.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Abciximab.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Abciximab.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Abciximab.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Abciximab.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Abciximab.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Abciximab.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Abciximab.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Abciximab.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Abciximab.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Abciximab.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Abciximab.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Abciximab.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Abciximab.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Abciximab.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Abciximab.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Abciximab.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Abciximab.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Abciximab.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Abciximab.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Abciximab.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Abciximab.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Abciximab.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Abciximab.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Abciximab.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Abciximab.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Abciximab.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Abciximab.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Abciximab.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Abciximab.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Abciximab.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Abciximab.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Abciximab.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Abciximab.

Target Protein

Integrin beta-3 ITGB3
Integrin alpha-IIb ITGA2B
Low affinity immunoglobulin gamma Fc region receptor II-a FCGR2A
Low affinity immunoglobulin gamma Fc region receptor II-b FCGR2B
Vitronectin VTN

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8121459
    Authors unspecified: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61.
  • PMID: 12939213
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Reopro
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Reopro
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Reopro
    Solution • 2 mg / mL • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul